Dyslipidemia News and Research

RSS

Dyslipidemia is a disruption in the amount of lipids in the blood.

FDA approves Daiichi Sankyo's sNDA for Welchol

Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.

7 Oct 2009

Eat strawberries to improve cholesterol levels

According to a new study published in the October 2009 issue of Nutrition Journal, women with metabolic syndrome had reduced total cholesterol levels - including LDL - after a brief period of daily consumption of a strawberry-based beverage.

6 Oct 2009

GVK Biosciences and Quantitative Solutions to develop and market clinical trial outcome databases

GVK Biosciences (GVK BIO), Asia’s leading integrated research services provider and Quantitative Solutions (QS), a modeling and simulation (M&S) consultancy to the pharmaceutical and biotech industry, announced a strategic partnership to develop and market clinical trial outcome databases.

5 Oct 2009

Orexigen's Empatic Phase 2b results demonstrate weight loss

Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.

1 Oct 2009

Karo Bio announces clinical phase II results of thyroid hormone analog eprotirome

The Swedish biotech company Karo Bio today announced that results from a clinical phase II study of the company’s thyroid hormone analog eprotirome, and its additive effects on dyslipidemia in ezetimibe-treated patients, are subject to a scientific presentation.

24 Sep 2009

Study compares annual healthcare costs of diabetic and non-diabetic individuals

Risk factors for metabolic syndrome, such as obesity, high blood pressure, and elevated blood lipid levels, can increase a person's healthcare costs nearly 1.6-fold, or about $2,000 per year. For each additional risk factor those costs rise an average of 24%, according to an illuminating article in a recent issue of Metabolic Syndrome and Related Disorders, a peer-reviewed journal published by Mary Ann Liebert, Inc.

18 Sep 2009

Karo Bio receives US patent for its thyroid hormone receptor platform

The Swedish biotech company Karo Bio today announced that it has expanded and further strengthened the intellectual property portfolio for its thyroid hormone receptor (TR) platform by entering into an agreement that provides Karo Bio with an exclusive license to a US patent from Pfizer Inc.

18 Sep 2009

Phase II VICTOR-E1 clinical study results reported

Schering-Plough Corporation today reported long-term data with vicriviroc, its investigational CCR5 receptor antagonist, from an ongoing, open-label extension of the Phase II VICTOR-E1 study in treatment-experienced HIV-infected patients.

15 Sep 2009

Quatrx' second phase 3 study of ospemifene tablets provides positive results

QuatRx Pharmaceuticals Company, a privately-held biopharmaceutical company, today announced positive efficacy results from the second of two patient cohorts in the second pivotal Phase 3 study for Ophena(TM) (ospemifene tablets), the company's investigational compound in development for the treatment of postmenopausal vulvovaginal atrophy (VVA).

10 Sep 2009

VIVUS' Phase 3 studies find Qnexa effective in tackling obesity

VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the safety and efficacy of Qnexa(TM), an investigational drug, in more than 3,750 patients across 93 sites. The EQUIP and CONQUER studies met all primary endpoints by demonstrating statistically significant weight loss with all three doses of Qnexa, as compared to placebo.

9 Sep 2009

Low HDL-cholesterol and high triglycerides linked to increased risk of CHD

Low levels of high-density lipoprotein cholesterol (HDL-C) and raised triglycerides, affecting millions of patients worldwide, are strongly linked to significantly increased risk of coronary heart disease (CHD) even in patients who achieve or surpass current low density lipoprotein cholesterol (LDL-C) targets.

3 Sep 2009

Combination of LIVALO and itraconazole drugs shows no adverse reactions

...

2 Sep 2009

High-density lipoprotein cholesterol concentrations increased in patients treated with LIVALO

New data presented today showed that in patients treated with LIVALO (pitavastatin), high-density lipoprotein cholesterol (HDL-C) concentrations increased, and nearly three-fourths of patients attained low-density lipoprotein cholesterol (LDL-C) targets, with results sustained over 52 weeks.

2 Sep 2009

DYSlipidemia International Study results presented at the ESC congress

According to a new analysis of 22,000 patients, nearly three-quarters of patients taking statins still had at least one lipid abnormality. These results, from a study conducted by Merck & Co., Inc., Whitehouse Station, N.J., U.S.A., which operates in many countries as Merck Sharp & Dohme Limited, were presented today at the European Society of Cardiology (ESC) congress in Barcelona, Spain.

31 Aug 2009

Karo Bio collaborates with Wyeth for treating inflammatory diseases

The Swedish biotech company Karo Bio today announced that beginning September 1, 2009, Wyeth will take on all future research and development activities under the drug discovery collaboration between the parties.

25 Aug 2009

Skin disease psoriasis associated with cardiovascular disease and increased mortality

The skin disease psoriasis is associated with atherosclerosis (a buildup of plaque in the arteries) characterized by an increased prevalence of ischemic heart disease, cerebrovascular disease, peripheral artery disease and an increased risk of death, according to a report in the June issue of Archives of Dermatology.

16 Jun 2009

Abbott and AstraZeneca to co-promote Trilipix (fenofibric acid)

Abbot and AstraZeneca have announced that they have entered into an agreement for AstraZeneca to co-promote Abbott's Trilipix (fenofibric acid), a medication for use alone or in combination with a statin to treat certain lipid disorders. Under the terms of the agreement, AstraZeneca will obtain the non-exclusive right to co-promote Trilipix alongside Abbott in the United States, excluding Puerto Rico. Specific financial terms were not disclosed.

5 Jun 2009

High blood pressure, diabetes and increased carotid artery wall thickness means increased risk of stroke

Increased carotid artery wall thickness (CAWT), which can cause heart attack and stroke in many patients, is significantly related to diabetes and hypertension, according to a study performed at A.O.U. in Cagliari Sardegna, Italy (Chairman, Professor Giorgio Mallarini).

23 Apr 2009

Too much sugar is bad, but which sugar is worse: Fructose or glucose?

In 2005, the average American consumed 64kg of added sugar, a sizeable proportion of which came through drinking soft drinks.

21 Apr 2009

In lab supplements of lipoic acid lower triglyceride levels

Studies done with laboratory rats suggest that supplementation of their diet with lipoic acid had a significant effect in lowering triglycerides, which along with cholesterol levels and blood pressure are one of the key risk factors in cardiovascular disease.

30 Mar 2009